-
Mashup Score: 2232
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 2231
Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms in adults, with meta-analytic calibrated subdistribution hazard ratio (sHRs) of 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA.1 In addition, when considering post-COVID thromboembolic and cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure (0·45 [0·38–0·53] 0–30 days after SARS-CoV-2 infection; 0·61 [0·51–0·73] 91–180 days after SARS-CoV-2 infection), venous thromboembolism (sHR 0·22 [95% CI 0·17–0·29] 0–30 days after SARS-CoV-2 infection; 0·53 [0·40–0·70] 91–180 days after SARS-CoV-2 infection), and arterial thrombosis (0·53 [0·44–0·63] 0–30 days after SARS-CoV-2 infection; 0·72 [0·
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 11
With a still-emerging understanding of the syndrome’s biology, researchers are braiding basic discoveries into treatment studies as they go
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 6Exercise Intolerance in Patients With Post-COVID Condition - 23 day(s) ago
This randomized crossover clinical trial investigates postexercise fatigue and physiologic characteristics among nonhospitalized patients with post-COVID condition compared with age- and sex-matched healthy controls.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2334Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease - 26 day(s) ago
Nature Immunology – Openshaw and colleagues find myeloid inflammation and complement activation signatures in patients with long COVID who were previously hospitalized.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 2268Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease - 26 day(s) ago
Nature Immunology – Openshaw and colleagues find myeloid inflammation and complement activation signatures in patients with long COVID who were previously hospitalized.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1320Exercise Intolerance in Patients With Post-COVID Condition - 28 day(s) ago
This randomized crossover clinical trial investigates postexercise fatigue and physiologic characteristics among nonhospitalized patients with post-COVID condition compared with age- and sex-matched healthy controls.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1064Exercise Intolerance in Patients With Post-COVID Condition - 1 month(s) ago
This randomized crossover clinical trial investigates postexercise fatigue and physiologic characteristics among nonhospitalized patients with post-COVID condition compared with age- and sex-matched healthy controls.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 2006
Nature – With key long COVID trials yet to yield results, people with the condition are trying to change how clinical trials are done.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 2
Nature – With key long COVID trials yet to yield results, people with the condition are trying to change how clinical trials are done.
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet
Vaccination reduced the risk of #LongCovid by ~40% in the entire population (5.4 million) of Norway https://t.co/pwVRT1fhh8 and reduced cardiovascular and thrombotic events @NhungPharma @LancetRespirMed https://t.co/DD1qAUKB2L